Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics

Laura Testa
Tagged:

Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal.Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its acquisition…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

…

This content is for Standard 1 Year members only.
Login Join Now